title: [Specific effect of attenuated strain of Francisella tularensis on the development of radiation induced lesions in experimental animals and effictiveness of antibacterial therapy for lesions induced by radiation combined with virulemt strain of the bacteria].
abstract: For study of the effects of whole-body gamma-radiation (1 and 4 Gy) on the response of the body to administration of vaccines and virulent strains of tularemia 206 outbred white mice were used. The results of the study shown that the administration of attenuated bacterial cells in 5 days after exposure to radiation (1 and 4 Gy) caused more severe post-radiation effects and the increase in the number of died animals. The severity of the disease was less if mice were vaccinated in 26 days after irradiation (4 Gy). The treatment of tularemia in irradiated mice twith Riphampicin (daily peroral administration, 5 mg/mouse, duration of treatment--7 days) administered in 4 hours after infection was effective and caused high survival of affected mice. The results show effectiveness of the riphampicin treatment of tularemia in the animals exposed to sublethal dose of radiation.
authors.forename: V S
authors.initials: VS
authors.lastname: Nesterenko
authors.forename: I S
authors.initials: IS
authors.lastname: Meshcheriakova
authors.forename: N P
authors.initials: NP
authors.lastname: Savina
authors.forename: E M
authors.initials: EM
authors.lastname: Iatsenko
authors.forename: M I
authors.initials: MI
authors.lastname: Kormilitsina
authors.forename: L A
authors.initials: LA
authors.lastname: Moiseeva
authors.forename: I L
authors.initials: IL
authors.lastname: Khakaiu
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001428:Bacterial Vaccines / Q000008:administration & dosage; D023482:Bioterrorism; D004334:Drug Administration Schedule; D005260:Female; D005604:Francisella tularensis / Q000276:immunology; D005720:Gamma Rays; D007279:Injections, Subcutaneous; D051379:Mice; D011833:Radiation Injuries, Experimental / Q000150:complications* / Q000503:physiopathology; D012293:Rifampin / Q000627:therapeutic use*; D014406:Tularemia / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000008:administration & dosage
chemical_list: D000900:Anti-Bacterial Agents; D001428:Bacterial Vaccines; D014613:Vaccines, Attenuated; D012293:Rifampin